Glaxo Operations UK Ltd.

The primary objective was to describe the long-term safety and tolerability of belimumab treatment in subjects with SSc-ILD by measuring the incidence of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs). The secondary objective was to describe the long-term effect of belimumab on lung function in subjects with SSc-ILD by measuring the absolute change from baseline in forced vital capacity (FVC).

Primary objective: Efficacy: To evaluate the therapeutic effect of two different doses of DAP/TOM for 24 weeks followed by Bepirovirsen 300 mg once weekly (including loading dose) for 24 weeks to achieve functional cure in chronic HBV infected subjects (receiving NA treatment; all subjects with no restriction on baseline HBsAg). Secondary objective: Efficacy: To evaluate the therapeutic effect of two different doses of DAP/TOM for 24 weeks followed by Bepirovirsen 300 mg once weekly (including loading dose) for 24 weeks to achieve functional cure in chronic HBV infected subjects (receiving NA treatment and baseline HBsAg>3000 IU/mL). Efficacy: To evaluate the therapeutic effect of two different doses of DAP/TOM or placebo for 24 weeks followed by Bepirovirsen 300 mg once weekly (including loading dose) for 24 weeks to achieve functional cure in chronic HBV infected subjects (receiving NA treatment and baseline HBsAg≤3000 IU/mL).

To evaluate the efficacy and safety of perioperative dostarlimab compared with SOC in subjects with untreated T4N0 or stage III (resectable) dMMR/MSI-H colon cancer